926037-48-1 Usage
Description
Supect, also known as Radotinib, is a tyrosine kinase inhibitor with a unique structure similar to the second-generation TKI, nilotinib. It is a potent compound that has been approved for the treatment of chronic myeloid leukemia (CML) and has shown significant in vitro activity against a variety of tumor cell lines. Supect is a promising pharmaceutical candidate for various applications due to its ability to induce cytotoxicity in c-KIT-positive malignancies, making it a potential target agent for the treatment of acute myeloid leukemia and small cell lung cancer.
Uses
Used in Oncology:
Supect is used as a second-line treatment for chronic myeloid leukemia (CML) due to its potent activity against tumor cell lines and its ability to inhibit the Bcr-Abl tyrosine kinase.
Used in Anticancer Applications:
Supect is used as a potential target agent for the treatment of acute myeloid leukemia and small cell lung cancer, as it can induce cytotoxicity in c-KIT-positive malignancies.
Used in COVID-19 Research:
Supect is a COVID-19-related research product, indicating its potential use in studying and treating the virus.
Used in Pharmaceutical Industry:
Supect is used as a tyrosine kinase inhibitor in the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells.
Originator
Il-Yang (Korea)
Indications
Radotinib (Supect(R), Il-Yang Pharmaceutical) is a Bcr–Abl inhibitor that was approved in South Korea in 2012 for the treatment of imatinib-resistant CML. Radotinib, which has a terminal 4-(pyridine-2-yl) pyrimidine moiety, was developed based on the previously approved Bcr–Abl inhibitors nilotinib. Radotinib has equivalent efficacy with that of other second-generation Bcr–Abl inhibitors and is well tolerated in chronic-phase CML patients. The lower cost of radotinib compared with other FDA-approved Bcr–Abl inhibitors makes it an attractive alternative for the treatment of CML in developing nations.
in vitro
radotinib couples to bcr-abl and reduce the phosphorylation of bcr-abl target protein crkl. the pre-clinical studies shows superiority of radotinib to imatinib in both wild-type and mutant bcr-abl1 positive cml cell lines. [1]
references
1. kim sh, menon h, jootar s et al. efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to bcr-abl1 tyrosine kinase inhibitors. haematologica. 2014 jul;99(7):1191-6.
Check Digit Verification of cas no
The CAS Registry Mumber 926037-48-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,6,0,3 and 7 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 926037-48:
(8*9)+(7*2)+(6*6)+(5*0)+(4*3)+(3*7)+(2*4)+(1*8)=171
171 % 10 = 1
So 926037-48-1 is a valid CAS Registry Number.
926037-48-1Relevant articles and documents
High-yield synthesis method of radotinib
-
, (2020/05/02)
The invention discloses a high-yield synthesis method of radotinib and relates to the technical field of drug organic synthesis. The method comprises the following steps that 3-acetamido-4-methylbenzoic acid as a starting raw material undergoes an amide condensation reaction with 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline to obtain an intermediate I, the intermediate I and cyanamide undergo an addition reaction to obtain an intermediate II, and the intermediate II and dimethylamino-1-(3-pyrazinyl)-2-propenyl-1-one undergo a ring-closure reaction to obtain radotinib. According to the method, the reaction operation is simplified, the cost investment is reduced, the generation amount of three wastes is reduced, the conversion rate of initial raw materials and intermediates is increased, and the total yield of the prepared radotinib can reach 79% or above.
N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
-
Page/Page column 19, (2008/06/13)
The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.
